Studies on the predictive factors of treatment outcome after intravitreal injection of Lucentis (ranibizumab) in eyes with macular edema associated with central retinal vein occlusion (CRVO)

Studies on the predictive factors of treatment outcome after intravitreal injection of Lucentis (ranibizumab) in eyes with macular edema associated with central retinal vein occlusion (CRVO) - Effect of ranibizumab in eyes with macular edema associated with CRVO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012793

Enrollment

Registered

2014-01-10

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central retinal vein occlusion

Interventions

Corrected visual acuity, visual filed, spectral-domain optical coherence tomography (SD-OCT), ultra wide-field fluorescein angiography, aqueous VEGF concentration, and new flicker electroretinogram (E

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Macular edema secondary to CRVO, Central macular thickness > 300 um, Duration after the onset < 12 months

Exclusion criteria

Exclusion criteria: Any history of previous treatments for CRVO

Design outcomes

Primary

Measure	Time frame
Corrected visual acuity, visual filed, spectral-domain optical coherence tomography (SD-OCT), ultra wide-field fluorescein angiography, and new flicker electroretinogram (ERG) using skin electrodes are performed before and after the treatment. Predictive factors of treatment outcome are statistically analyzed.	—

Countries

Japan

Contacts

Public ContactMineo Kondo

Mie University Hospital Ophthalmology

Mineo@clin.medic.mie-u.ac.jp059-231-5027

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026